Join the 1,512 others who are receiving high-signal, data-driven analysis to be in front of their peers in the cannabinoid space! If you have found value in our insights please share this with another canna-curious individual to grow the revolution!

Each month we spend hours analyzing market research, data trends and private conservations to will keep you in front of the ever-evolving cannabinoid industry. Read the entire June Report here

One Report, Once a Month, Everything you need to know

The article below is an excerpt from the Monthly Playbook.

laptop-img
Get In touch With Us

Action-Oriented problem solvers ready to go

One Report Once a Month Everything you Need to know

From executive-level strategy to technical know-how, our actionable insights keep you ahead of the pack!

Join the 1,512 others who are receiving high-signal, data-driven analysis to be in front of their peers in the cannabinoid space! If you have found value in our insights please share this with another canna-curious individual to grow the revolution!

Each month we spend hours analyzing market research, data trends and private conservations to will keep you in front of the ever-evolving cannabinoid industry. Read the entire June Report here

One Report, Once a Month, Everything you need to know

The article below is an excerpt from the Monthly Playbook.

Almost a century of cannabis prohibition has dramatically hindered scientific discovery and contributions to original knowledge about the effects and utilities of its botanical products. Academic science, which traditionally would have been expected to play an active role in this endeavor, has instead been limited by funding constraints and the study of NIDA-provided cannabis that does not represent what is available in the market. Currently, it is unreasonable to assume that such entities can pivot quickly and effectively.

There is a lack of any institutional knowledge base or understanding of the parallel, real-world advances now emerging from alternative community-based efforts as the tide turns towards widespread normalization and legalization of cannabis. Our non-profit (501c3) organization provides a compelling and complimentary alternative. We represent the ability to harness a more virtual and flexible collaborative approach to scientific advancement predicated on our team’s successful track record, as our members have been operating in the cannabis and cannabinoid science space for almost a decade and in the biotechnology industry and clinical arena across multiple decades. We have embraced an “act first, talk later” operating principle that has now led to a successful series of disruptive innovations in the cannabis science space.

How We Break Down The Cannabis Industry ’s Product Taxonomy

CANNABIS INDUSTRY SEGMENT Lifestyle MEDICINAL: HEALTH &   DISEASE
Dietary
     Supp- lement
Drug
MODE / ROUTE OF ADMINISTRATION Inhaled Ingested Applied Ingested Inhaled Ingested Applied
CLASS OF   STARTING MATERIAL Hemp
Cannabis
PRODUCTION   SCALE Boutique / Artisinal /   Craƒ
Commercial
Agricultural   Commodity
PRODUCT GOAL RBS      
(Processed) Botanical   Substance
Botanical Product
   NDI API

How we operate

As part of our intent to remain “meta”, the CESC is gaining acceptance and credibility as a neutral organization that performs product validations. Our position provides us with the foundation to accept grants and donations to carry out our initiatives and objectives. This, in turn, brings benefit to supply chain participants and to the greater community. We envision a validated product “formulary” that other industry participants and consumers can access. Our objective creates a reliable corpus of products to access for study or dependable use. Furthermore, we propose to identify products in this formulary by providing a certification mark that also communicates complex product content information in an easily understood format (the ChemoMark™).

Why we remain “meta”

As a nonprofit organization, the CESC positions itself as impartial and neutral to vested interests in the cannabinoid botanical industry. This permits our organization to develop best practices and guidance without being directed by special interests or stakeholders with private agendas. Our founders value their ability to contribute to original knowledge and anchor this with a long track record in bioscience and medicine. The CESC considers its non-profit status to be a general benefit to the cannabis industry as it establishes collaborations with private, for-profit industry participants and sponsors. We understand cannabis industry product taxonomy.

How we study the overlapping parameters, influencing effects & adverse events

How We Break Down The Cannabis Industry ’s Product Taxonomy

Our Initiative

The CESC has established primary clinical programs that investigate the efficacy of cannabinoid botanical products. These clinical correlates initiatives center on The Dosing Project™, a Phase IV approach to clinical study. To complement a classical medicinal phased development program, we deploy a paradigm-shifting clinical study approach. The Dosing Project™ initiates our investigations by defining product dose-effect relationships for general neurophysiological indications, such as mood, sleep, pain, and appetite. Further clinical studies delve into evaluations of mood, concentration, and cognitive functioning using EEG and other biomarkers in a more traditional, phased-trial approach. We have also initiated clinical programs on the neuro-inflammatory processes affected by cannabinoid botanical products and their clinical effects on Alzheimer’s, autism, traumatic brain injuries, and nociceptive and neuropathic pain.

Our Focus

Our view is that the current regulatory climate surrounding the evolving acceptance and legalization of cannabinoid botanical products focuses primarily on aspects of product safety. Testing of such products involves determination of adulterants, including pesticides, heavy metals, residual solvents, and microbial bioburden. The CESC considers an investigation of adverse events (AE) to be an unmet product safety need for cannabinoid botanical products. This still leaves a big gap in the industry as far as determining product quality attributes. Such characteristics include chemotype, stability, and anticipated effects. From a producer perspective, understanding and appropriately exploiting such parameters helps with development decisions and offers opportunities for market segmentation and increases in market share. We therefore have positioned our investigations in this arena.

Our Study

Medicine development has long been the purview of white men. Historically, they provided the predominant manpower to advance these efforts. Additionally, white men provided the predominant group of subjects for clinical studies. We now understand the importance of stratifying such investigations to include women, different ethnic groups, and different age groups in order to better understand and fine tune the administration of medicines to individuals. This appreciation of study stratification has been in the DNA of the CESC since its founding. Incorporating gender, ethnicity, and age group into our ongoing studies of cannabinoid botanical products is integral and essential in our programs.

laptop-img
Get In touch With Us

Action-Oriented problem solvers ready to go

One Report Once a Month Everything you Need to know

From executive-level strategy to technical know-how, our actionable insights keep you ahead of the pack!

Join the 1,512 others who are receiving high-signal, data-driven analysis to be in front of their peers in the cannabinoid space! If you have found value in our insights please share this with another canna-curious individual to grow the revolution!

Each month we spend hours analyzing market research, data trends and private conservations to will keep you in front of the ever-evolving cannabinoid industry. Read the entire June Report here

One Report, Once a Month, Everything you need to know

The article below is an excerpt from the Monthly Playbook.

How does Lumber future influence the industrial hemp market?

Lumber futures prices rose the maximum amount allowed by the Chicago Mercantile Exchange (CME) for 42% of the trading days in April. The boom in the housing market has caused lumber prices to soar, increasing the average lumber price for building a new house by $36,000 from last year.

FUTURE TIMBER PRICES

The increased price is forcing consumers to take a closer look at alternative building materials. We believe that hempcrete is poised to emerge as the best alternative to the traditional wood-framed house. There are several companies in the United States and Canada that have been developing unique ways of using hemp hurd, water, and lime to generate hempcrete.

Hemp hurd is the wood part of industrial hemp’s stalk that’s revealed after the fiber has been removed via decortication, and decortation is the process of separating the outside bast fibers from the hurd, of the plant. The remaining hurd is the main ingredient in most hempcretes.

There has been a 2.5% increase in industrial seed pricing this year, which could signal more farmers to turn to industrial hemp crops, supporting the rise of hemprete as a viable building material. As we see it, there are several companies in the United States and Canada poised to take advantage of this historical opportunity as we see it. These are our favorites:

The voyage had begun, and had begun happily with a soft blue sky, and a calm sea.

laptop-img
Get In touch With Us

Action-Oriented problem solvers ready to go

One Report Once a Month Everything you Need to know

From executive-level strategy to technical know-how, our actionable insights keep you ahead of the pack!

Join the 1,512 others who are receiving high-signal, data-driven analysis to be in front of their peers in the cannabinoid space! If you have found value in our insights please share this with another canna-curious individual to grow the revolution!

Each month we spend hours analyzing market research, data trends and private conservations to will keep you in front of the ever-evolving cannabinoid industry. Read the entire June Report here

One Report, Once a Month, Everything you need to know

The article below is an excerpt from the Monthly Playbook.

Letter From The Team – June 2021 Monthly Playbook

In the past, this piece has been used to discuss current events and how they’ll influence the future of the cannabinoid space. By cross-referencing conversations with industry leaders with both new and ongoing monthly trends in the
market, we identify the important nuggets of wisdom that are crucial to finding success.

This month, the Eighth team thinks it’s crucial to take a slightly different approach and focus solely on
the announcement of Trulieve’s acquisition of Harvest Health. This Florida kingpin has made waves by taking over the largest operator in Arizona in an all-stock deal, bumping its national presence from six states up to 11. Now, analysts speculate that the combined revenue of Harvest Health and Trulieve “will surpass $1.2 billion by the end of the year.”2 In other words, it will become one of the biggest operators in the game.

[T]he long-term benefits of immediately building solid structures in each key state are vital to continued growth.

Trulieve’s business model

For those who are unfamiliar with Trulieve’s business model, they operate according to something called the ‘hub-and spoke’ model. Simple in concept and perfect for reaching such segmented markets with unique, state-determined obstacles, this approach leverages several regional offices, as opposed to operating in one headquartered location. Companies like Trulieve are using this approach to strategically build large-scale operational functionality right out of the gate, and while this isn’t the best approach for the companies looking to pinch pennies in the short term, the long-term benefits of immediately building solid structures in each key state are vital to continued growth.

Trulieve needs to figure out how to combine the different SOPs, tech stacks,and employees, all while striving to improve upon efficiencies

Upfront cost

The upfront cost involved might deter some operators, specifically those with a short-term mindset. When long-term possibilities are neglected, assets that were once built on a solid foundation begin to shatter. This is especially true when taking federal legalization into account. Trulieve CEO Kim Rivers explains it best, stating that the company “think[s] about it more as a distribution play,” and that this is the first step toward creating “national distribution models” that will “help drive efficiencies in each region.”2

Now, it’s clear that Trulieve has made a move that strategically, financially, and geographically benefits them, but the next big question revolves around the execution. How will Trulieve integrate Harvest Health into their operations?

Though the acquisition is a massive win by Rivers and her team, it isn’t a home run until all the bases are cleared. Before they can dominate, Trulieve needs to figure out how to combine the different SOPs, tech stacks, and employees, all while striving to improve upon efficiencies, as Rivers previously stated.

As the space continues to shift and consolidate, it’s important to monitor situations like these so that they may provide a model for you and your own business. This type of cannibalistic expansion will continue to occur as the industry works through its growing pains, but as always, we’ll keep you updated along the way so you can feel armed with actionable knowledge.

laptop-img
Get In touch With Us

Action-Oriented problem solvers ready to go

One Report Once a Month Everything you Need to know

From executive-level strategy to technical know-how, our actionable insights keep you ahead of the pack!